Pretreatment or posttreatment with aripiprazole attenuates methamphetamine-induced stereotyped behavior in mice

Nobue Kitanaka, Junichi Kitanaka, F. Scott Hall, Masaru Kayama, Hironobu Sugimori, George R. Uhl, Motohiko Takemura

Research output: Contribution to journalArticlepeer-review


Aripiprazole is a third-generation atypical antipsychotic and a dopamine D2 receptor partial agonist. In the present study, we investigated whether a single administration of aripiprazole to mice, either as a pretreatment or as a posttreatment, would affect stereotypy induced by methamphetamine (METH). Pretreatment of male ICR mice with aripiprazole (1 or 10 mg/kg, i.p.) attenuated the incidence of METH-induced stereotypical behavior in a dose-dependent manner. Pretreatment of mice with 1 mg/kg aripiprazole produced an increase in the locomotor activity in mice treated with METH compared with mice treated with vehicle plus METH and with 10 mg/kg aripiprazole plus METH. This increase in locomotion is indicative of a rightward shift in the dose-response curve for METH, consistent with a shift in the type of stereotypical behavior observed from biting to sniffing. Aripiprazole posttreatment, after METH-induced stereotypical behavior, was fully expressed and also significantly attenuated overall stereotypy in an aripiprazole dose-dependent manner. These data suggest that the antagonism of METH effects by aripiprazole should be investigated as a potential treatment for acute METH overdose.

Original languageEnglish (US)
Pages (from-to)11-10
Number of pages2
JournalJournal of Experimental Neuroscience
StatePublished - 2015
Externally publishedYes


  • Aripiprazole
  • Dopamine receptor
  • Methamphetamine
  • Stereotyped behavior

ASJC Scopus subject areas

  • Neuroscience(all)


Dive into the research topics of 'Pretreatment or posttreatment with aripiprazole attenuates methamphetamine-induced stereotyped behavior in mice'. Together they form a unique fingerprint.

Cite this